

Product description

The Anti-EBV Latent Membrane Protein 1 [CS 1-4] antibody is specific for Epstein-Barr virus infected cells expressing the latent membrane protein (LMP). This is a combination of four pooled antibodies (CS.1, CS.2, CS.3, and CS.4 in a ratio of 2:2:1:1) which collectively detect the latent membrane protein (LMP) of EBV, an important effector protein in B-cell transformation under EBV infection, across 20 geographically distinct EBV isolates.

Name: Anti-EBV Latent Membrane Protein 1 [CS 1-4]

Species Reactivity: EBV

Host Species: Mouse

Clonality: Monoclonal

Clone: CS1-4

Isotype: IgG1

Target: Latent membrane protein 1 (LMP1), 57- 66 kDa

Immunogen: Fusion protein containing 189 a.a of the C-terminus of LMP-1

Conjugate: Unconjugated

Myeloma used: P3X63Ag8.653

Applications: IHC; IHC; IF; IP; WB

Recommended controls: EBV transformed lymphoblastoid cell lines

Hybridoma culture conditions: RPMI 1640 with 10% FCS and 1 mM pyruvate. For revival from nitrogen stocks or if the growth flags, supplement with 10% BM Condimed HI (Roche Diagnostics).

Contributor(s)

Inventor: Martin Rowe

Institute: University of Birmingham, UK

Properties

Format: Liquid

Concentration: 1 mg/ml

Unit size: 100 ug

Storage buffer: PBS with 0.02% azide

Storage conditions: -20° C. Avoid repeated freeze / thaw cycles.

Shipping conditions: Dry ice

Purification: Affinity chromatography

Purity: Greater than 90%, as determined by SDS-PAGE

Directions for use: WB- 0.2µg/ml; IF- 1µg/ml (Suggested dilutions).

The applications listed for this monoclonal antibody are derived from information supplied by the originating laboratory and/or relevant published literature. These applications have not been independently validated by CancerTools.org. End users are responsible for performing appropriate titration and optimization for their experimental system. Application-specific guidelines will be provided when available.

References

- Ye et al. 2020. J Cancer. 11(5):1257-1269. PMID: 31956372.
- Shi et al. 2019. Theranostics. 9(9):2424-2438. PMID: 31131045.
- Wang et al. 2017. Virol Sin. 32(5):423-430. PMID: 29116594.
- Martin et al. 2016. J Virol. 90(19):8520-30. PMID: 27440880.
- Castrale et al. 2011. J Transplant. 2011:865957. PMID: 21559262.
- Flanagan et al. 2003. J Gen Virol. 84(Pt 7):1871-9. PMID: 12810882.
- Localization of the Epstein-Barr virus protein LMP 1 to exosomes.
- Nakatsuka et al. 2002. J Clin Oncol. 20(20):4255-60. PMID: 12377970.
- Pyothorax-associated lymphoma: a review of 106 cases.
- Xu et al. 2002. J Virol. 76(8):4080-6. PMID: 11907247.
- Ascani et al. 1997. Ann Oncol. 8(11):1133-8. PMID: 9426333.
- Rowe et al. 1991. J Exp Med. 173(1):147-58. PMID: 1845872.
- Rowe et al. 1987. J Gen Virol. 68 (Pt 6):1575-86. PMID: 2438376.

Material Citation

If use of this material results in a scientific publication, please cite the material in the following manner: Anti-EBV Latent Membrane Protein 1 [CS 1-4] antibody was invented by Martin Rowe at University of Birmingham, UK (CancerTools.org, 151471).

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

While CancerTools.org has made all reasonable efforts to ensure that the information provided by CancerTools.org and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.